Company / Total Assets
Neurocrine Biosciences Total Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$4.6B
FY2025
5-year range
$2.1B / $4.6B
FY2021-FY2025
Trend
+24.5%
vs FY2024
Sector context
#28 of 214
Health Care
What the data says
Neurocrine Biosciences's total assets of $4.6B is higher than 87% of companies in the Health Care sector (FY2025). Total Assets has increased for 9 consecutive years, from $365M in FY2016 to $4.6B in FY2025.
Based on SEC 10-K filings.
$4.6B in FY2025 with a 5-year CAGR of +21.7%. Top quartile in the Health Care sector.
Improved from $3.3B to $4.6B over the past 2 years.
Health Care sector context is included.
Total Assets over time
Growth rates
- 3-Year CAGR
- +25.0%
- 5-Year CAGR
- +21.7%
- 10-Year CAGR
- -
Sector benchmark
Top 13% in Health CareTop 13% of 214This company $4.6B Sector average $7.5B
▼
-38.0% below sector average
Key checks
Key Insights
- Neurocrine Biosciences's total assets has grown for 9 consecutive years.
- 5-year CAGR of +21.7%, indicating consistent growth.
- In FY2025, total assets increased 24.5% year-over-year.
- Ranks #28 out of 214 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.6B | +24.5% |
| FY2024 | $3.7B | +14.4% |
| FY2023 | $3.3B | +37.3% |
| FY2022 | $2.4B | +14.3% |
| FY2021 | $2.1B | +19.5% |
| FY2020 | $1.7B | +32.8% |
| FY2019 | $1.3B | +31.5% |
| FY2018 | $993.2M | +21.5% |
| FY2017 | $817.6M | +123.9% |
| FY2016 | $365.1M | -23.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026